These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415 [TBL] [Abstract][Full Text] [Related]
17. A comparative review of classification systems in myelodysplastic syndromes (MDS). Bennett JM Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011 [TBL] [Abstract][Full Text] [Related]
18. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234 [TBL] [Abstract][Full Text] [Related]
19. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Hasle H; Baumann I; Bergsträsser E; Fenu S; Fischer A; Kardos G; Kerndrup G; Locatelli F; Rogge T; Schultz KR; Starý J; Trebo M; van den Heuvel-Eibrink MM; Harbott J; Nöllke P; Niemeyer CM; Leukemia; 2004 Dec; 18(12):2008-14. PubMed ID: 15496981 [TBL] [Abstract][Full Text] [Related]